AngioDynamics Inc. has announced the commencement of the RECOVER-AV clinical trial, marking the enrollment of the first patient. This multi-center, multi-national study aims to evaluate the AlphaVac Multipurpose Mechanical Aspiration $(MMA)$ F1885 System for the treatment of acute, intermediate-risk pulmonary embolism (PE). The trial will involve up to 20 hospital-based sites across Europe, Canada, and Hong Kong. The primary safety endpoint will assess the incidence of adverse events through 12 months, with functional and quality-of-life outcomes evaluated at 30 days and 12 months. Additional investigations, including Cardiac MRI and exercise testing, will contribute to a comprehensive assessment of long-term recovery. Results from the trial are anticipated in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.